Kalaris Therapeutics, Inc. announced the appointment of Liisa Bayko as Chief Financial Officer and Treasurer, effective July 20, 2026, with an annualized base salary of $475,000 and a 40.0% target annual incentive bonus. Additionally, Brett Hagen resigned as Chief Accounting Officer effective July 27, 2026, and Amy Vandekop was designated as interim principal accounting officer effective the same date. Kalaris Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.
